Dr. Thomas Herzog on Who Benefits From Neoadjuvant Therapies

November 6, 2015
Thomas Herzog, MD

Thomas Herzog, MD, clinical director, University of Cincinnati Cancer Institute, discusses the types of patients who benefit from neoadjuvant therapies. Patients who cannot undergo aggressive cytoreduction, patients with comorbidities and older patients would be ideal candidates to receive the therapy, he adds.

Thomas Herzog, MD, clinical director, University of Cincinnati Cancer Institute, discusses the types of patients who benefit from neoadjuvant therapies. Patients who cannot undergo aggressive cytoreduction, patients with comorbidities and older patients would be ideal candidates to receive the therapy, he adds.

Herzog says, in most cases, depending on the patient’s health, primary cytoreduction would be the ideal way to go for treatment. While he considers neoadjuvant therapies to be a standard of care, he does not consider them to be the standard of care.